D. Boral Capital Reiterates “Buy” Rating for Hoth Therapeutics (NASDAQ:HOTH)

Hoth Therapeutics (NASDAQ:HOTH)‘s stock had its “buy” rating restated by analysts at D. Boral Capital in a report issued on Thursday,Benzinga reports. They currently have a $5.00 price target on the stock. D. Boral Capital’s price objective would suggest a potential upside of 284.62% from the stock’s current price.

Separately, Wall Street Zen upgraded Hoth Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 31st. One investment analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Hoth Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $4.00.

Hoth Therapeutics Price Performance

Shares of HOTH opened at $1.30 on Thursday. The stock has a 50-day moving average of $0.93 and a 200-day moving average of $1.02. The company has a market cap of $17.17 million, a PE ratio of -0.98 and a beta of 0.55. Hoth Therapeutics has a one year low of $0.58 and a one year high of $3.80.

Hoth Therapeutics (NASDAQ:HOTH) last issued its earnings results on Monday, May 12th. The company reported ($0.27) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.07. Analysts expect that Hoth Therapeutics will post -1.36 EPS for the current fiscal year.

Hedge Funds Weigh In On Hoth Therapeutics

A hedge fund recently raised its stake in Hoth Therapeutics stock. Geode Capital Management LLC raised its stake in shares of Hoth Therapeutics, Inc. (NASDAQ:HOTH) by 15.7% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 95,946 shares of the company’s stock after purchasing an additional 13,038 shares during the period. Geode Capital Management LLC owned approximately 1.39% of Hoth Therapeutics worth $72,000 as of its most recent SEC filing. 7.08% of the stock is owned by institutional investors.

About Hoth Therapeutics

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.